Drugs / SSGJ-705
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06390774 | May 2024 → Dec 2026 expected | — | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05145179 | Dec 2021 → Dec 2023 | — | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07646626 | Jul 2026 → Jun 2027 expected | cancer of unknown primary site | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
| Phase 2 | NCT07022002 | Jul 2025 → Dec 2026 expected | — | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSGJ-705 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07646626 ↗ |
| Route | Intravenous | “administered via intravenous (IV) infusion” NCT05145179 ↗ |